Archive for March, 2008



GlaxoSmithKline pulled Lapdap (chloroproguanil-dapsone) from the market and ended the development of Dacart (Lapdap+artesunate) after phase III trials of the drugs showed significant hemoglobin reductions in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Patient’s with G6PD deficiency have weaker red blood cell membranes which can rupture when exposed to oxidative stress caused by certain drugs […]

My goal for the blog is to achieve one post every day. Clearly, I’ve missed that mark, blogging while traveling is a trick which might take me some time to master. Until then, my apologies for any lapses in news and comments.
Last week Nature carried a commentary from Mark Grabowsky, malaria manager at the Global […]